AFAP1 and non-small cell lung carcinoma: Some studies have suggested that AFAP1-AS1 can activate the PI3K/AKT pathway and interact with EZH2 to inhibit the apoptosis of A549/DDP cells, thereby inducing NSCLC resistance to DDP [36].